These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23932362)

  • 1. Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.
    Pitini V; Arrigo C; Di Mirto C; Mondello P; Altavilla G
    Lung Cancer; 2013 Oct; 82(1):171-2. PubMed ID: 23932362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
    Hammerman PS; Sos ML; Ramos AH; Xu C; Dutt A; Zhou W; Brace LE; Woods BA; Lin W; Zhang J; Deng X; Lim SM; Heynck S; Peifer M; Simard JR; Lawrence MS; Onofrio RC; Salvesen HB; Seidel D; Zander T; Heuckmann JM; Soltermann A; Moch H; Koker M; Leenders F; Gabler F; Querings S; Ansén S; Brambilla E; Brambilla C; Lorimier P; Brustugun OT; Helland A; Petersen I; Clement JH; Groen H; Timens W; Sietsma H; Stoelben E; Wolf J; Beer DG; Tsao MS; Hanna M; Hatton C; Eck MJ; Janne PA; Johnson BE; Winckler W; Greulich H; Bass AJ; Cho J; Rauh D; Gray NS; Wong KK; Haura EB; Thomas RK; Meyerson M
    Cancer Discov; 2011 Jun; 1(1):78-89. PubMed ID: 22328973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.
    Beauchamp EM; Woods BA; Dulak AM; Tan L; Xu C; Gray NS; Bass AJ; Wong KK; Meyerson M; Hammerman PS
    Mol Cancer Ther; 2014 Feb; 13(2):475-82. PubMed ID: 24296828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.
    Bai Y; Kim JY; Watters JM; Fang B; Kinose F; Song L; Koomen JM; Teer JK; Fisher K; Chen YA; Rix U; Haura EB
    Cancer Res; 2014 Dec; 74(24):7217-7228. PubMed ID: 25348954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia.
    Nagao T; Takahashi N; Kameoka Y; Noguchi S; Shinohara Y; Ohyagi H; Kume M; Sawada K
    Intern Med; 2013; 52(22):2567-71. PubMed ID: 24240798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.
    Day E; Waters B; Spiegel K; Alnadaf T; Manley PW; Buchdunger E; Walker C; Jarai G
    Eur J Pharmacol; 2008 Dec; 599(1-3):44-53. PubMed ID: 18938156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
    Faber E; Mojzikova R; Plachy R; Rozmanova S; Stastny M; Divoka M; Jarosova M; Indrak K; Divoky V
    Leuk Res; 2010 Apr; 34(4):e91-3. PubMed ID: 19811824
    [No Abstract]   [Full Text] [Related]  

  • 9. A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.
    Cea M; Cirmena G; Garuti A; Rocco I; Palermo C; Cagnetta A; Moran E; Colombo N; Grasso R; Fugazza G; Gobbi M; Nencioni A; Ballestrero A; Patrone F
    Leuk Res; 2010 Sep; 34(9):e240-2. PubMed ID: 20447687
    [No Abstract]   [Full Text] [Related]  

  • 10. Dasatinib in chronic myelogenous leukemia.
    Chu SC; Tang JL; Li CC
    N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
    [No Abstract]   [Full Text] [Related]  

  • 11. F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
    Oyekunle AA; Castagnetti F; Gugliotta G; Soverini S; Baccarani M; Rosti G
    Leuk Res; 2011 Jul; 35(7):e118-20. PubMed ID: 21489624
    [No Abstract]   [Full Text] [Related]  

  • 12. NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.
    Xu C; Buczkowski KA; Zhang Y; Asahina H; Beauchamp EM; Terai H; Li YY; Meyerson M; Wong KK; Hammerman PS
    Mol Cancer Ther; 2015 Oct; 14(10):2382-2389. PubMed ID: 26206333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.
    Hayette S; Chabane K; Michallet M; Michallat E; Cony-Makhoul P; Salesse S; Maguer-Satta V; Magaud JP; Nicolini FE
    Leuk Res; 2011 Jan; 35(1):38-43. PubMed ID: 20673586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new target for therapy in squamous cell carcinoma of the lung.
    Ohashi K; Pao W
    Cancer Discov; 2011 Jun; 1(1):23-4. PubMed ID: 22586316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discoidin domain receptor 2 signaling networks and therapy in lung cancer.
    Payne LS; Huang PH
    J Thorac Oncol; 2014 Jun; 9(6):900-4. PubMed ID: 24828669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
    Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M
    J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651
    [No Abstract]   [Full Text] [Related]  

  • 17. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.
    Hedberg ML; Goh G; Chiosea SI; Bauman JE; Freilino ML; Zeng Y; Wang L; Diergaarde BB; Gooding WE; Lui VW; Herbst RS; Lifton RP; Grandis JR
    J Clin Invest; 2016 Jan; 126(1):169-80. PubMed ID: 26619122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer.
    Nicoś M; Powrózek T; Krawczyk P; Jarosz B; Pająk B; Sawicki M; Kucharczyk K; Trojanowski T; Milanowski J
    Med Oncol; 2014 Oct; 31(10):176. PubMed ID: 25173530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia.
    Nishimoto M; Nakamae H; Koh KR; Kosaka S; Matsumoto K; Morita K; Koh H; Nakane T; Ohsawa M; Hino M
    Acta Haematol; 2013; 130(2):111-4. PubMed ID: 23548721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
    Frigeri F; Arcamone M; Luciano L; Di Francia R; Pane F; Pinto A
    Blood; 2009 May; 113(20):5028-9. PubMed ID: 19443672
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.